Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Comenzo RL, Fein DE, Hassoun H, Bello C, Chou JF, Devlin S et al. Long-term outcomes of patients with systemic light chain amyloidosis (AL) treated at diagnosis with risk-adapted stem cell transplant and consolidation with novel agents. ASH Annu Meet Abstr 2012; 120: 3150.

    Google Scholar 

  2. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720–5726.

    CAS  PubMed  Google Scholar 

  3. Douglas KW, Parker AN, Hayden PJ, Rahemtulla A, D'Addio A, Lemoli RM et al. Plerixafor for PBSC mobilisation in myeloma patients with advanced renal failure: safety and efficacy data in a series of 21 patients from Europe and the USA. Bone Marrow Transplant 2012; 47: 18–23.

    Article  CAS  PubMed  Google Scholar 

  4. Dunn D, Vikas P, Jagasia M, Savani BN . Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant 2012; 47: 1136–1137.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to E Kaul.

Ethics declarations

Competing interests

RLC: consultant/scientific advisor, Takeda, Prothena; clinical research funding, Takeda, Prothena, Teva. The other authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kaul, E., Shah, G., Chaulagain, C. et al. Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis. Bone Marrow Transplant 49, 1233 (2014).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links